Volume 25, Number 2—February 2019
Dispatch
Crimean-Congo Hemorrhagic Fever, Kosovo, 2013–2016
Table 2
Clinical and laboratory findings and their association with death in patients with Crimean-Congo hemorrhagic fever, Kosovo, 2013–2016*
Finding | OR for death if present (95% CI) | p value |
---|---|---|
Clinical findings significantly associated with death | ||
Coma | 35.0 (3.32–369) | 0.003 |
Somnolence | 27.0 (3.80–192) | 0.001 |
Fasciculations† | NA (25.2 [2.45–259]) | NA (0.007) |
Hemoperitoneum | 16.6 (2.47–112) | 0.004 |
Hematemesis | 11.4 (1.74–74.7) | 0.011 |
Bleeding gums | 11.3 (2.04–63.1) | 0.006 |
Ecchymoses | 7.31 (1.25–42.8) | 0.027 |
Melena | 7.20 (1.31–39.6) | 0.023 |
Petechiae | 6.67 (1.31–34.0) | 0.023 |
>4 of the 5 previous findings | 24.0 (2.33–247) | 0.008 |
Diarrhea | 7.20 (1.31–39.6) | 0.023 |
Jaundice† |
NA (7.87 [0.71–87.3]) |
NA (0.093) |
Clinical findings not significantly associated with death | ||
Vertigo | 5.00 (0.53–47.3) | 0.160 |
Female sex | 3.56 (0.50–25.6) | 0.206 |
Epistaxis | 2.08 (0.46–9.51) | 0.343 |
Sweats | 2.00 (0.11–35.4) | 0.636 |
Joint pain | 1.92 (0.43–8.61) | 0.391 |
Headache | 1.31 (0.29–5.89) | 0.723 |
Conjunctivitis | 1.31 (0.29–5.89) | 0.723 |
Abdominal pain | 1.20 (0.23–6.34) | 0.830 |
Tiredness | 1.05 (0.08–13.1) | 0.968 |
Bradycardia | 1.05 (0.08–13.1) | 0.968 |
Metrorrhagia | 0.95 (0.08–11.1) | 0.968 |
Hypotension | 0.87 (0.19–4.03) | 0.864 |
Muscular pain | 0.75 (0.11–5.32) | 0.774 |
Vomiting | 0.52 (0.12–2.32) | 0.391 |
Hyperemia | 0.42 (0.09–1.86) | 0.251 |
Anorexia | 0.28 (0.04–2.01) | 0.206 |
Nausea | 0.25 (0.03–2.40) | 0.230 |
Hiccup† | NA (4.67 [0.37–58.3]) | NA (0.232) |
Hypertension† | NA (2.10 [0.12–37.1]) | NA (0.613) |
Ribavirin not given |
1.059 (0.162–6.94) |
0.952 |
Laboratory findings significantly associated with death | ||
VL >1 × 108.5 | 80.0 (6.3–1,011) | 0.001 |
LDH >3,500 U/L† | NA (26.7 [2.24–317]) | NA (0.009) |
LDH >2,700 U/L | 37.5 (2.77–507) | 0.006 |
Leukocytes >7.7 | 15.8 (1.53–164) | 0.020 |
Leukocytes >8.0† | NA (16.7 [1.62–172]) | NA (0.018) |
Platelets <50.000/µL |
5.25 (1.07–25.8) |
0.041 |
Laboratory findings not significantly associated with death | ||
ALT >168 U/L | 3.20 (0.48–21.2) | 0.228 |
AST >147 U/L | 2.75 (0.52–14.4) | 0.232 |
CK >1,037 | 1.95 (0.44–8.55) | 0.376 |
IgG <2.5‡ | NA (4.67 [0.45–48.3]) | NA (0.196) |
IgM <2.5‡ | NA (4.67 [0.45–48.3]) | NA (0.196) |
*ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; LDH, lactate dehydrogenase; NA, not applicable; OR, odds ratio; VL, viral load.
†The OR could not be determined because there were no survivors with this symptom. The value in parentheses would have been obtained if 1 hypothetical survivor had this symptom or test result.
‡The OR could not be determined because there were no deaths among patients with this finding. The value in parentheses would have been obtained if 1 hypothetical fatal case had this test result.
1These first authors contributed equally to this article.
Page created: January 18, 2019
Page updated: January 18, 2019
Page reviewed: January 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.